These findings suggest that targeting TGF‐β1 signaling may offer promising therapeutic strategies for LAA strokes, while CXCR4 inhibition could benefit CE strokes, providing etiology‐specific approaches to improve AIS outcomes. This evidence concerns the gene TGFB1 and androgen insensitivity syndrome.